Nigen Biotech, L.L.C. v. Ken Paxton

804 F.3d 389, 2015 U.S. App. LEXIS 17223, 2015 WL 5749618
CourtCourt of Appeals for the Fifth Circuit
DecidedSeptember 30, 2015
Docket14-10923
StatusPublished
Cited by137 cases

This text of 804 F.3d 389 (Nigen Biotech, L.L.C. v. Ken Paxton) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nigen Biotech, L.L.C. v. Ken Paxton, 804 F.3d 389, 2015 U.S. App. LEXIS 17223, 2015 WL 5749618 (5th Cir. 2015).

Opinion

EDITH H. JONES, Circuit Judge:

A manufacturer and distributor of over-the-counter dietary supplements, Isodrene and The HCG Solution, appeals the district court’s order dismissing its constitutional and state law claims against the Attorney General of the State of Texas on the sole basis of state sovereign immunity. We conclude that it is at least partially correct that NiGen’s claims are not barred from federal jurisdiction on the basis of Ex parte Young-, federal jurisdiction plainly exists over most of the constitutional claims pled; and NiGen has standing to sue. Accordingly, we affirm in part, and vacate and remand in part for further. proceedings.

BACKGROUND

NiGen makes and sells dietary supplements, two of which contain the “individual amino acid building blocks” of prescription-drug ingredient hCG. 1 The company labels the packages of these products with the term “hCG,” which the Attorney General of the State of Texas (the “AG” or the State) determined was “false, misleading, or deceptive” in violation of the Texas Deceptive Trade Practices Act (“DTPA”) because, among other reasons, “the claim is trying to mimic claims that FDA considers off-label for the prescription drug.” In October 2011, the AG sent letters to this effect to NiGen and its retailers, including CVS, Walgreens, and Wal-Mart, intimating that formal enforcement was on the horizon for both -NiGen and the retailers. The retailers pulled the products from their shelves in Texas and other states, allegedly costing NiGen millions of dollars in lost revenue.

NiGen filed suit in December 2011 under 42 U.S.C. § 1983, alleging violations of its rights under the First Amendment, Fourteenth Amendment Due Process and Equal Protection Clauses, the Commerce Clause, and the Supremacy Clause. The company also alleged a state law claim of tortious interference with existing business relations. NiGen sought 1) a declaration that its labeling did not violate federal law and that it was entitled to use “HCG” on its labels; 2) preliminary and permanent injunctive relief; 3) money damages; and 4) costs and attorneys’ fees.

The AG moved for dismissal, alleging both jurisdictional and pleading defects. As for the jurisdictional claims, the AG argued that the plaintiff lacked Article III standing because the only injury to NiGen was the result of third-party action; that the “federal statutory claim” was non-justi-ciable because NiGen asked for a declara *393 tion that its labeling did riot violate FDA law, though the AG was never attempting to enforce federal law; and that state sovereign immunity barred the money damages and state law claims. The AG alternatively averred that NiGen’s claims fail to state a claim as required by Federal Rule of Civil Procedure 12(b)(6). Substantial briefing and pretrial motions preceded the submission of these motions to the court in July 2012.

For reasons not apparent in the record, the district court did not rule for almost two years. Then, despite the plethora of jurisdictional issues before it, the court dismissed the entire case as barred by state sovereign immunity. NiGen seasonably appealed.

STANDARD OF REVIEW

We review the trial court’s jurisdictional determinations de novo. Fontenot v. McCraw, 777 F.3d 741, 746 (5th Cir.2015). “The question of whether state defendants are entitled to sovereign immunity is likewise reviewed de novo.” Moore v. La. Bd. of Elementary & Secondary Educ., 743 F.3d 959, 962 (5th Cir.2014); see also Hale v. King, 642 F.3d 492, 497 (5th Cir.2011) (per curiam). We review the court’s rulings on Rule 12(b)(6) motions de novo and must determine whether the pleaded facts state plausible claims that are cognizable in law. Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570, 127 S.Ct. 1955, 1974, 167 L.Ed.2d 929 (2007). Federal courts may analyze arguments that question our jurisdiction in any order. In this unusual situation, all of the jurisdie-tional arguments must be addressed for NiGen’s suit to proceed in federal court.

DISCUSSION

The district court concluded that state sovereign immunity barred NiGen’s entire suit and therefore pretermitted analysis of the AG’s other arguments. The district court cited Aguilar v. Texas Department of Criminal Justice for the broad proposition that “a suit against state officials that is in fact a suit against a State is barred regardless of whether it seeks damages or injunctive relief.” 160 F.3d 1052, 1053 (5th Cir.1998) (quoting Pennhurst State Sch. & Hosp. v. Halderman, 465 U.S. 89, 102, 104 S.Ct. 900, 909, 79 L.Ed.2d 67 (1984)). This is deficient not least because shortly thereafter the opinion acknowledges the availability of Ex parte Young suits to enforce federal law. 2 Rather than fully .defend the district court’s reasoning, the AG resurrects its original arguments against federal jurisdiction and raises new ones.

A. State Sovereign Immunity

The several states of our union retained those aspects of sovereignty that the people did not explicitly assign to the federal government. 3 Since the judicial article does not “create new and unheard of remedies,” Hans v. Louisiana, 134 U.S. 1, 12, 10 S.Ct. 504, 506, 33 L.Ed. 842 (1890), the sovereign states cannot be sued without their consent. See Papasan v. Attain, 478 U.S. 265, 276, 106 S.Ct. 2932, 2939, 92 L.Ed.2d 209 (1986). As a result, “Federal courts are without jurisdiction over suits against a state, a state agency, *394 or a state official in his official capacity unless that state has waived its sovereign immunity or Congress has clearly abrogated it.” Moore, 743 F.3d at 963. Texas has not consented by statute, and § 1983 does not abrogate state sovereign immunity. Quern v. Jordan, 440 U.S. 332, 340, 99 S.Ct. 1139, 1145, 59 L.Ed.2d 358 (1979).

“A suit is not ‘against’ a state, howeyer, when it seeks prospective, injunc-tive relief from a state actor ... based on an alleged ongoing violation of the federal constitution.” K.P. v. LeBlanc, 729 F.3d 427, 439 (5th Cir.2013). Under the doctrine articulated in Ex parte Young, 4 209 U.S. 123, 28 S.Ct. 441, 52 L.Ed. 714 (1908), a state official attempting to enforce an unconstitutional law “is stripped of his official clothing and becomes a private person subject to suit.” K.P. v. LeBlanc, 627 F.3d 115, 124 (5th Cir.2010).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
804 F.3d 389, 2015 U.S. App. LEXIS 17223, 2015 WL 5749618, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nigen-biotech-llc-v-ken-paxton-ca5-2015.